BFC Planning, Inc.’s Xenon Pharmaceuticals XENE Stock Holding History

BFC Planning, Inc.’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.56K	Hold	59	–	–	﹤0.01%	2807
2026 Q1	$3.43K	Hold	59	–	–	﹤0.01%	2445
2025 Q4	$2.64K	Hold	59	–	–	﹤0.01%	2551
2025 Q3	$2.37K	Hold	59	–	–	﹤0.01%	2431
2025 Q2	$1.85K	Hold	59	–	–	﹤0.01%	2326
2025 Q1	$1.98K	Hold	59	–	–	﹤0.01%	2309
2024 Q4	$2.31K	Buy	+59	New	+$2.44K	﹤0.01%	2251

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BFC Planning, Inc.'s XENE Position: Q2 2026 in Review

BFC Planning, Inc. held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 59 shares worth $3.56K. The position accounts for ﹤0.01% of the portfolio, ranked #2807.

BFC Planning, Inc. first reported a position in XENE in Q4 2024 and has held it in 7 quarters since. 317 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

BFC Planning, Inc. held 59 shares of Xenon Pharmaceuticals worth $3.56K as of Q2 2026.
BFC Planning, Inc. left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #2807 holding.
BFC Planning, Inc. first reported a position in Xenon Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
317 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.